{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:00:58Z","timestamp":1769025658522,"version":"3.49.0"},"reference-count":210,"publisher":"European Respiratory Society (ERS)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2010,7,16]]},"published-print":{"date-parts":[[2011,3]]},"abstract":"<jats:p>Much remains unknown about latent infection with<jats:italic>Mycobacterium tuberculosis<\/jats:italic>. Existing immunodiagnostic tools for this condition have various limitations, most importantly in their ability to predict disease. Randomised controlled trials have established protective efficacy of isoniazid therapy for 6\u201312 months among non-HIV-infected and HIV-infected subjects. While efficacy may reach 90%, acceptance and adherence to prolonged therapy are less than desired. Rifampicin plus pyrazinamide for 2 months, though efficacious, has been associated with excess hepatotoxicity in non-HIV-infected persons. Isoniazid plus rifampicin for 3 months has proven efficacy, but adverse effects may be more frequent than isoniazid or rifampicin monotherapy. Rifampicin monotherapy for 3\u20134 months is well tolerated, but efficacy data are currently limited, and concerns remain over possible selection of rifampicin-resistant mutants. For contacts of patients with multidrug-resistant tuberculosis, expert opinions differ on whether to treat with at least two drugs or just a fluoroquinolone, and for how long. With the existing diagnostic and treatment tools, efficacy of preventive therapy does not necessarily translate into field effectiveness. A targeted approach is required to maximise cost-effectiveness. Each geographic region needs to set its own priority after taking into account available scientific data and local circumstances.<\/jats:p>","DOI":"10.1183\/09031936.00079310","type":"journal-article","created":{"date-parts":[[2010,8,7]],"date-time":"2010-08-07T00:47:32Z","timestamp":1281142052000},"page":"690-711","source":"Crossref","is-referenced-by-count":89,"title":["Treatment of latent infection with<i>Mycobacterium tuberculosis<\/i>: update 2010"],"prefix":"10.1183","volume":"37","author":[{"given":"C.C.","family":"Leung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.L.","family":"Rieder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Lange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.W.","family":"Yew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2010,8,6]]},"reference":[{"key":"2024102020245561000_37.3.690.1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.0010005"},{"key":"2024102020245561000_37.3.690.2","first-page":"151","article-title":"The arcana of tuberculosis","volume":"78","author":"Grigg","year":"1958","journal-title":"Am Rev Tuberc Pulmon Dis"},{"key":"2024102020245561000_37.3.690.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2009.01692.x"},{"key":"2024102020245561000_37.3.690.4","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00033010"},{"key":"2024102020245561000_37.3.690.5","unstructured":"World Health Organization . Global tuberculosis control: a short update to the 2009 report. WHO\/HTM\/TB\/2009.426. Geneva, World Health Organization, 2009."},{"key":"2024102020245561000_37.3.690.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.7.677"},{"key":"2024102020245561000_37.3.690.7","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00120908"},{"key":"2024102020245561000_37.3.690.8","unstructured":"Canetti G . Les r\u00e9infections tuberculeuses latentes du poumon. Etude anatomo-pathologique, bact\u00e9riologique et pathog\u00e9nique des l\u00e9sions tuberculeuses abortives autres que de primo-infection. [Anatomical-pathological, bacteriological, and pathogenetic study of abortive, non-primary tuberculosis lesions.] Paris, Vigot Fr\u00e8res, 1939."},{"key":"2024102020245561000_37.3.690.9","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.6.2706-2708.2003"},{"key":"2024102020245561000_37.3.690.10","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2307\/4589873","article-title":"Tuberculosis prophylaxis trials in review","volume":"72","author":"Ferebee","year":"1957","journal-title":"Public Health Rep"},{"key":"2024102020245561000_37.3.690.11","first-page":"CD001363","article-title":"Isoniazid for preventing tuberculosis in non-HIV infected persons","volume":"1","author":"Smieja","year":"1999","journal-title":"Cochrane Database Syst Rev"},{"key":"2024102020245561000_37.3.690.12","first-page":"CD000171","article-title":"Treatment of latent tuberculosis infection in HIV infected persons","volume":"1","author":"Akolo","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2024102020245561000_37.3.690.13","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/140.5.1189"},{"key":"2024102020245561000_37.3.690.14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1128\/AAC.40.3.552","article-title":"Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide","volume":"40","author":"Dhillon","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"2024102020245561000_37.3.690.15","first-page":"1102","article-title":"British Thoracic and Tuberculosis Association. Short-course chemotherapy in pulmonary tuberculosis: a controlled trial by the British Thoracic and Tuberculosis Association","volume":"2","year":"1976","journal-title":"Lancet"},{"key":"2024102020245561000_37.3.690.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)95623-0"},{"key":"2024102020245561000_37.3.690.17","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1164\/ajrccm.150.5.7952564","article-title":"Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice","volume":"150","author":"Chapuis","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102020245561000_37.3.690.18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040344"},{"key":"2024102020245561000_37.3.690.19","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200905-0795OC"},{"key":"2024102020245561000_37.3.690.20","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200407-885OC"},{"key":"2024102020245561000_37.3.690.21","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200807-1029OC"},{"key":"2024102020245561000_37.3.690.22","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200711-1736OC"},{"key":"2024102020245561000_37.3.690.23","unstructured":"Scottish Intercollegiate Guidelines Network . SIGN 50: A guideline developer's handbook, Annex B. www.sign.ac.uk\/guidelines\/fulltext\/50\/annexb.html Date last accessed: February 2, 2010."},{"key":"2024102020245561000_37.3.690.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0966-842X(98)01216-5"},{"key":"2024102020245561000_37.3.690.25","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(03)00741-2"},{"key":"2024102020245561000_37.3.690.26","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-009-8450-7"},{"key":"2024102020245561000_37.3.690.27","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-008-8087-y"},{"key":"2024102020245561000_37.3.690.28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1462-5822.2009.01325.x"},{"key":"2024102020245561000_37.3.690.29","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1128\/iai.37.3.1042-1049.1982","article-title":"Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions","volume":"37","author":"Wayne","year":"1982","journal-title":"Infect Immun"},{"key":"2024102020245561000_37.3.690.30","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.627-631.2005"},{"key":"2024102020245561000_37.3.690.31","first-page":"317","article-title":"Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis","volume":"10","author":"Hu","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102020245561000_37.3.690.32","doi-asserted-by":"publisher","DOI":"10.1128\/JB.00926-09"},{"key":"2024102020245561000_37.3.690.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.2007.06078.x"},{"key":"2024102020245561000_37.3.690.34","doi-asserted-by":"publisher","DOI":"10.1128\/JB.182.22.6358-6365.2000"},{"key":"2024102020245561000_37.3.690.35","doi-asserted-by":"publisher","DOI":"10.1084\/jem.104.5.763"},{"key":"2024102020245561000_37.3.690.36","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.4.16141"},{"key":"2024102020245561000_37.3.690.37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.4326.721"},{"key":"2024102020245561000_37.3.690.38","unstructured":"Styblo K . Epidemiology of tuberculosis. Royal Netherlands Tuberculosis Association Selected Papers. The Hague, Royal Netherlands Tuberculosis Association, 1991."},{"key":"2024102020245561000_37.3.690.39","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.supplement_3.ats600"},{"key":"2024102020245561000_37.3.690.40","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/oxfordjournals.aje.a121593","article-title":"The prognosis of a positive tuberculin reaction in childhood and adolescence","volume":"99","author":"Comstock","year":"1974","journal-title":"Am J Epidemiol"},{"key":"2024102020245561000_37.3.690.41","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/152.3.247"},{"key":"2024102020245561000_37.3.690.42","first-page":"392","article-title":"The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era","volume":"8","author":"Marais","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102020245561000_37.3.690.43","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200404-512OC"},{"key":"2024102020245561000_37.3.690.44","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.12.1297"},{"key":"2024102020245561000_37.3.690.45","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn075"},{"key":"2024102020245561000_37.3.690.46","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2009.506"},{"key":"2024102020245561000_37.3.690.47","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200711-1613OC"},{"key":"2024102020245561000_37.3.690.48","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-11-200812020-00248"},{"key":"2024102020245561000_37.3.690.49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001379"},{"key":"2024102020245561000_37.3.690.50","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2008.01470.x"},{"key":"2024102020245561000_37.3.690.51","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-3-200808050-00241"},{"key":"2024102020245561000_37.3.690.52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001441"},{"key":"2024102020245561000_37.3.690.53","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00045509"},{"key":"2024102020245561000_37.3.690.54","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00140009"},{"key":"2024102020245561000_37.3.690.55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011670"},{"key":"2024102020245561000_37.3.690.56","doi-asserted-by":"publisher","DOI":"10.1378\/chest.76.6.771"},{"key":"2024102020245561000_37.3.690.57","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200210-1125OC"},{"key":"2024102020245561000_37.3.690.58","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/147.4.1062"},{"key":"2024102020245561000_37.3.690.59","first-page":"434","article-title":"Various combinations of isoniazid with streptomycin or with PAS in the treatment of pulmonary tuberculosis: Seventh report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee","volume":"1","year":"1955","journal-title":"BMJ"},{"key":"2024102020245561000_37.3.690.60","first-page":"917","article-title":"Studies on prevention of experimental tuberculosis with isoniazid. II. Effects of different dosage regimens","volume":"74","author":"Ferebee","year":"1956","journal-title":"Am Rev Tuberc"},{"key":"2024102020245561000_37.3.690.61","first-page":"942","article-title":"Prophylactic effects of isoniazid on primary tuberculosis in children; a preliminary report","volume":"76","author":"Ferebee","year":"1957","journal-title":"Am Rev Tuberc"},{"key":"2024102020245561000_37.3.690.62","first-page":"810","article-title":"Isoniazid prophylaxis in an undeveloped area","volume":"86","author":"Comstock","year":"1962","journal-title":"Am Rev Respir Dis"},{"key":"2024102020245561000_37.3.690.63","first-page":"490","article-title":"Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts","volume":"85","author":"Ferebee","year":"1962","journal-title":"Am Rev Respir Dis"},{"key":"2024102020245561000_37.3.690.64","first-page":"821","article-title":"The effect of isoniazid prophylaxis on tuberculosis morbidity among household contacts of previously known cases of tuberculosis","volume":"85","author":"Mount","year":"1962","journal-title":"Am Rev Respir Dis"},{"key":"2024102020245561000_37.3.690.65","first-page":"161","article-title":"A controlled trial of isoniazid prophylaxis in mental institutions","volume":"88","author":"Ferebee","year":"1963","journal-title":"Am Rev Respir Dis"},{"key":"2024102020245561000_37.3.690.66","first-page":"28","article-title":"Controlled chemoprophylaxis trials in tuberculosis. A general review","volume":"17","author":"Ferebee","year":"1970","journal-title":"Adv Tuberc Res"},{"key":"2024102020245561000_37.3.690.67","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1984.03340340023018"},{"key":"2024102020245561000_37.3.690.68","first-page":"419","article-title":"The use of isoniazid among household contacts of open cases of pulmonary tuberculosis","volume":"33","author":"Egsmose","year":"1965","journal-title":"Bull World Health Organ"},{"key":"2024102020245561000_37.3.690.69","first-page":"277","article-title":"Chemoprophylaxis in the Philippines. A controlled pilot study among household contacts of tuberculosis cases","volume":"7","author":"Del Castillo","year":"1965","journal-title":"Bull Quezon Institute"},{"key":"2024102020245561000_37.3.690.70","first-page":"169","article-title":"Long term isoniazid prophylaxis. Controlled trial on INH prophylaxis after recent tuberculin conversion in young adults","volume":"41","author":"Veening","year":"1968","journal-title":"Bull Int Un Against Tuber"},{"key":"2024102020245561000_37.3.690.71","doi-asserted-by":"publisher","DOI":"10.1378\/chest.73.1.44"},{"key":"2024102020245561000_37.3.690.72","first-page":"555","article-title":"International Union Against Tuberculosis, Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis","volume":"60","year":"1982","journal-title":"Bull World Health Organ"},{"key":"2024102020245561000_37.3.690.73","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/145.1.36"},{"key":"2024102020245561000_37.3.690.74","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1097\/00007890-199457110-00029","article-title":"A double-blind randomized controlled trial of primary isoniazid prophylaxis in dialysis and transplant patients","volume":"57","author":"John","year":"1994","journal-title":"Transplantation"},{"key":"2024102020245561000_37.3.690.75","first-page":"827","article-title":"Isoniazid prophylaxis among Alaskan Eskimos: a final report of the Bethel Isoniazid Studies","volume":"119","author":"Comstock","year":"1979","journal-title":"Am Rev Respir Dis"},{"key":"2024102020245561000_37.3.690.76","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?","volume":"3","author":"Comstock","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102020245561000_37.3.690.77","first-page":"1","article-title":"Controlling tuberculosis in the United States: recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America","volume":"54","author":"Taylor","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"2024102020245561000_37.3.690.78","doi-asserted-by":"crossref","first-page":"407","DOI":"10.7326\/0003-4819-76-3-112-6-407","article-title":"A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen","volume":"112","author":"Cohn","year":"1990","journal-title":"Ann Intern Med"},{"key":"2024102020245561000_37.3.690.79","doi-asserted-by":"publisher","DOI":"10.1086\/598192"},{"key":"2024102020245561000_37.3.690.80","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-71-6-1113"},{"key":"2024102020245561000_37.3.690.81","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1164\/arrd.1972.106.3.357","article-title":"Isoniazid-associated hepatitis. Report of an outbreak","volume":"106","author":"Garibaldi","year":"1972","journal-title":"Am Rev Respir Dis"},{"key":"2024102020245561000_37.3.690.82","first-page":"991","article-title":"Isoniazid-related hepatitis: A US Public Health Service cooperative surveillance study","volume":"117","author":"Kopanoff","year":"1978","journal-title":"Am Rev Respir Dis"},{"key":"2024102020245561000_37.3.690.83","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1986.03380190099036"},{"key":"2024102020245561000_37.3.690.84","doi-asserted-by":"publisher","DOI":"10.1378\/chest.99.2.465"},{"key":"2024102020245561000_37.3.690.85","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.11.1014"},{"key":"2024102020245561000_37.3.690.86","first-page":"735","article-title":"Update: Adverse event data and revised American Thoracic Society\/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection \u2013 United States, 2003","volume":"52","year":"2003","journal-title":"MMWR"},{"key":"2024102020245561000_37.3.690.87","doi-asserted-by":"publisher","DOI":"10.1378\/chest.62.1.71"},{"key":"2024102020245561000_37.3.690.88","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2165\/00003495-198223010-00003","article-title":"Adverse effects of antituberculosis drugs","volume":"23","author":"Girling","year":"1982","journal-title":"Drugs"},{"key":"2024102020245561000_37.3.690.89","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.167.4.603"},{"key":"2024102020245561000_37.3.690.90","unstructured":"World Health Organization . Treatment of Tuberculosis. Guidelines for National Programmes: 4th Edn. WHO\/HTM\/TB\/2009.420. Geneva, World Health Organization, 2010."},{"key":"2024102020245561000_37.3.690.91","unstructured":"Yew WW . Chemotherapy including drug-resistant therapy and future developments. In: Davies PDO Barnes PF Gordon SB , eds. Clinical Tuberculosis. 4th Edn. Oxford, Hodder Arnold, 2008; pp. 225\u2013242."},{"key":"2024102020245561000_37.3.690.92","doi-asserted-by":"publisher","DOI":"10.1016\/0041-3879(80)90038-0"},{"key":"2024102020245561000_37.3.690.93","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198903023200901"},{"key":"2024102020245561000_37.3.690.94","doi-asserted-by":"publisher","DOI":"10.1126\/science.1086845"},{"key":"2024102020245561000_37.3.690.95","doi-asserted-by":"publisher","DOI":"10.1086\/498315"},{"key":"2024102020245561000_37.3.690.96","first-page":"895","article-title":"Tuberculin reactivity and the risk of tuberculosis: a review","volume":"4","author":"Watkins","year":"2000","journal-title":"Int J Tubercle Lung Dis"},{"key":"2024102020245561000_37.3.690.97","doi-asserted-by":"publisher","DOI":"10.1086\/597351"},{"key":"2024102020245561000_37.3.690.98","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91817-6"},{"key":"2024102020245561000_37.3.690.99","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709183371201"},{"key":"2024102020245561000_37.3.690.100","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199707313370505"},{"key":"2024102020245561000_37.3.690.101","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199707000-00006"},{"key":"2024102020245561000_37.3.690.102","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199818000-00014"},{"key":"2024102020245561000_37.3.690.103","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-200111010-00018"},{"key":"2024102020245561000_37.3.690.104","doi-asserted-by":"publisher","DOI":"10.1157\/13048575"},{"key":"2024102020245561000_37.3.690.105","first-page":"1114","article-title":"Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease","volume":"11","author":"Mohammed","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102020245561000_37.3.690.106","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200111090-00009"},{"key":"2024102020245561000_37.3.690.107","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200101260-00011"},{"key":"2024102020245561000_37.3.690.108","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200905-0708ED"},{"key":"2024102020245561000_37.3.690.109","unstructured":"World Medical Association . The Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. www.wma.net\/e\/ethicsunit\/helsinki.htm Last updated: 2002. Date last accessed: February 10, 2010."},{"key":"2024102020245561000_37.3.690.110","first-page":"25691","article-title":"International Conferenceon Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use","volume":"62","year":"1997","journal-title":"E6: Good Clinical Practice: Consolidated Guideline"},{"key":"2024102020245561000_37.3.690.111","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)06532-X"},{"key":"2024102020245561000_37.3.690.112","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7753(00)71496-5"},{"key":"2024102020245561000_37.3.690.113","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.11.1445"},{"key":"2024102020245561000_37.3.690.114","doi-asserted-by":"publisher","DOI":"10.1157\/13102265"},{"key":"2024102020245561000_37.3.690.115","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-8-200210150-00007"},{"key":"2024102020245561000_37.3.690.116","doi-asserted-by":"publisher","DOI":"10.1378\/chest.124.6.2112"},{"key":"2024102020245561000_37.3.690.117","first-page":"276","article-title":"Tuberculosis Prevention Working Group. Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus?","volume":"9","author":"Tortajada","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102020245561000_37.3.690.118","doi-asserted-by":"publisher","DOI":"10.1086\/520983"},{"key":"2024102020245561000_37.3.690.119","doi-asserted-by":"publisher","DOI":"10.1157\/13102264"},{"key":"2024102020245561000_37.3.690.120","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200404-478OC"},{"key":"2024102020245561000_37.3.690.121","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-10-200811180-00003"},{"key":"2024102020245561000_37.3.690.122","doi-asserted-by":"publisher","DOI":"10.1086\/422724"},{"key":"2024102020245561000_37.3.690.123","first-page":"289","article-title":"Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection \u2013 New York and Georgia, 2000","volume":"50","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024102020245561000_37.3.690.124","first-page":"733","article-title":"Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society\/ CDC recommendations \u2013 United States, 2001","volume":"50","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024102020245561000_37.3.690.125","doi-asserted-by":"publisher","DOI":"10.1086\/444463"},{"key":"2024102020245561000_37.3.690.126","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.4.1296"},{"key":"2024102020245561000_37.3.690.127","doi-asserted-by":"publisher","DOI":"10.1086\/499244"},{"key":"2024102020245561000_37.3.690.128","doi-asserted-by":"publisher","DOI":"10.1086\/375072"},{"key":"2024102020245561000_37.3.690.129","first-page":"334","article-title":"Observations on the combined use of pyrazinamide (Aldinamide) and isoniazid in the treatment of pulmonary tuberculosis; a clinical study","volume":"69","author":"Campagna","year":"1954","journal-title":"Am Rev Tuberc"},{"key":"2024102020245561000_37.3.690.130","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200206-626OC"},{"key":"2024102020245561000_37.3.690.131","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200802-355OC"},{"key":"2024102020245561000_37.3.690.132","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/143.2.262"},{"key":"2024102020245561000_37.3.690.133","doi-asserted-by":"publisher","DOI":"10.1086\/422645"},{"key":"2024102020245561000_37.3.690.134","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200901-0078OC"},{"key":"2024102020245561000_37.3.690.135","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00006205"},{"key":"2024102020245561000_37.3.690.136","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.154.5.8912767"},{"key":"2024102020245561000_37.3.690.137","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.155.5.9154885"},{"key":"2024102020245561000_37.3.690.138","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.17.1863"},{"key":"2024102020245561000_37.3.690.139","doi-asserted-by":"publisher","DOI":"10.1378\/chest.130.6.1712"},{"key":"2024102020245561000_37.3.690.140","first-page":"160","article-title":"Successful use of rifampicin for Hispanic foreign-born patients with latent tuberculosis infection","volume":"12","author":"Haley","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102020245561000_37.3.690.141","doi-asserted-by":"publisher","DOI":"10.1086\/647944"},{"key":"2024102020245561000_37.3.690.142","unstructured":"A Randomized ClinicalTrial Comparing 4RIF vs 9INH for Treatment of Latent Tuberculosis Infection (LTBI) \u2013 Effectiveness. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00931736 Date last updated: August 10, 2010. Date last accessed: March 31, 2010."},{"key":"2024102020245561000_37.3.690.143","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.55.11.887"},{"key":"2024102020245561000_37.3.690.144","doi-asserted-by":"publisher","DOI":"10.1086\/427802"},{"key":"2024102020245561000_37.3.690.145","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1164\/ajrccm.162.3.9804117","article-title":"Twice weekly isoniazid and rifampin treatment of latent tuberculosis infection in Canadian plains Aborigines","volume":"162","author":"McNab","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102020245561000_37.3.690.146","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1164\/ajrccm.150.5.7952564","article-title":"Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice","volume":"150","author":"Chapuis","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102020245561000_37.3.690.147","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1128\/AAC.43.9.2126","article-title":"Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis","volume":"43","author":"Miyazaki","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2024102020245561000_37.3.690.148","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200512-1953OC"},{"key":"2024102020245561000_37.3.690.149","unstructured":"TBTC Study26:WeeklyRFP\/INHfor3mo. vs. Daily INH for 9 mo. for the Treatment of LTBI. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00023452 Date last updated: July 26, 2010. Date last accessed: March 31, 2010."},{"key":"2024102020245561000_37.3.690.150","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200225020-00005"},{"key":"2024102020245561000_37.3.690.151","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342090-00003"},{"key":"2024102020245561000_37.3.690.152","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e31814a586a"},{"key":"2024102020245561000_37.3.690.153","doi-asserted-by":"publisher","DOI":"10.1086\/515174"},{"key":"2024102020245561000_37.3.690.154","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e3283339309"},{"key":"2024102020245561000_37.3.690.155","unstructured":"World Health Organization . Anti-tuberculosis Drug Resistance in the World. WHO\/TB\/97.229. Geneva, World Health Organization, 1997."},{"key":"2024102020245561000_37.3.690.156","first-page":"91","article-title":"Treatment of tuberculosis. The Mitchell Lecture 1979","volume":"14","author":"Mitchison","year":"1980","journal-title":"J Roy Coll Phys London"},{"key":"2024102020245561000_37.3.690.157","doi-asserted-by":"publisher","DOI":"10.3201\/eid1205.050681"},{"key":"2024102020245561000_37.3.690.158","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)11467-8"},{"key":"2024102020245561000_37.3.690.159","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200208-951OC"},{"key":"2024102020245561000_37.3.690.160","first-page":"431","article-title":"Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees","volume":"133","author":"Nolan","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"2024102020245561000_37.3.690.161","doi-asserted-by":"publisher","DOI":"10.1086\/595689"},{"key":"2024102020245561000_37.3.690.162","first-page":"19","article-title":"Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review","volume":"10","author":"Fraser","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102020245561000_37.3.690.163","doi-asserted-by":"publisher","DOI":"10.1542\/peds.109.5.765"},{"key":"2024102020245561000_37.3.690.164","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/00006454-199906000-00004","article-title":"Evaluation of young children in household contact with adult multidrug-resistant pulmonary tuberculosis cases","volume":"8","author":"Schaaf H","year":"1999","journal-title":"Pediatr Infect Dis J"},{"key":"2024102020245561000_37.3.690.165","first-page":"12","article-title":"Chapter 4: childhood contact screening and management. [Official Statement. Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. Chapter 4 in the series.]","volume":"11","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102020245561000_37.3.690.166","first-page":"59","article-title":"Management of persons exposed to multidrugresistant tuberculosis","volume":"41","year":"1992","journal-title":"MMWR Recomm Rep"},{"key":"2024102020245561000_37.3.690.167","doi-asserted-by":"publisher","DOI":"10.1592\/phco.22.9.701.34065"},{"key":"2024102020245561000_37.3.690.168","first-page":"131","article-title":"Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis","volume":"167","author":"Papastavros","year":"2002","journal-title":"CMAJ"},{"key":"2024102020245561000_37.3.690.169","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.6.1264"},{"key":"2024102020245561000_37.3.690.170","doi-asserted-by":"publisher","DOI":"10.1378\/chest.124.4.1476"},{"key":"2024102020245561000_37.3.690.171","unstructured":"World Health Organization . Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis \u2013 Emergency Update 2008. WHO\/HTM\/TB\/2008.402. Geneva, World Health Organization, 2008. WHO\/HTM\/TB\/2008.402."},{"key":"2024102020245561000_37.3.690.172","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200901-0146OC"},{"key":"2024102020245561000_37.3.690.173","doi-asserted-by":"publisher","DOI":"10.1054\/tube.2001.0288"},{"key":"2024102020245561000_37.3.690.174","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.157.6.9707037"},{"key":"2024102020245561000_37.3.690.175","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09742-8"},{"key":"2024102020245561000_37.3.690.176","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0711697105"},{"key":"2024102020245561000_37.3.690.177","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M803899200"},{"key":"2024102020245561000_37.3.690.178","doi-asserted-by":"publisher","DOI":"10.1126\/science.1106753"},{"key":"2024102020245561000_37.3.690.179","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00566-08"},{"key":"2024102020245561000_37.3.690.180","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00898-06"},{"key":"2024102020245561000_37.3.690.181","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200711-1736OC"},{"key":"2024102020245561000_37.3.690.182","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01204-07"},{"key":"2024102020245561000_37.3.690.183","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808427"},{"key":"2024102020245561000_37.3.690.184","unstructured":"Public Health Agency of Canada and Canadian Lung Association . Canadian Tuberculosis Standards. Ottawa, Public Health Agency of Canada and Canadian Lung Association, 2007."},{"key":"2024102020245561000_37.3.690.185","unstructured":"World Health Organization . TB\/HIV Clinical Manual. Geneva, World Health Organization, 2008."},{"key":"2024102020245561000_37.3.690.186","unstructured":"National Institute for Health and Clinical Excellence . Clinical Diagnosis and Management of Tuberculosis, and Measures for its Prevention and Control. London, National Institute for Health and Clinical Excellence, 2006."},{"key":"2024102020245561000_37.3.690.187","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/adc.78.2.169","article-title":"Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis","volume":"78","author":"Ormerod","year":"1998","journal-title":"Arch Dis Child"},{"key":"2024102020245561000_37.3.690.188","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200510-1666ST"},{"key":"2024102020245561000_37.3.690.189","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.22.2776"},{"key":"2024102020245561000_37.3.690.190","first-page":"S384","article-title":"Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999","volume":"7","author":"Jereb","year":"2003","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102020245561000_37.3.690.191","first-page":"925","article-title":"Evaluation of a tuberculosis screening program for high-risk students in Toronto schools","volume":"153","author":"Yuan","year":"1995","journal-title":"CMAJ"},{"key":"2024102020245561000_37.3.690.192","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-0394"},{"key":"2024102020245561000_37.3.690.193","doi-asserted-by":"publisher","DOI":"10.1378\/chest.113.5.1184"},{"key":"2024102020245561000_37.3.690.194","first-page":"1235","article-title":"Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada","volume":"12","author":"Hirsch-Moverman","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102020245561000_37.3.690.195","first-page":"S363","article-title":"Evaluation of tuberculosis contact investigations in California","volume":"7","author":"Sprinson","year":"2003","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102020245561000_37.3.690.196","doi-asserted-by":"publisher","DOI":"10.1016\/S0749-3797(02)00583-4"},{"key":"2024102020245561000_37.3.690.197","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0749-3797(18)31204-2","article-title":"Tuberculosis prevention: cost-effectiveness analysis of isoniazid chemoprophylaxis","volume":"4","author":"Rose","year":"1988","journal-title":"Am J Prev Med"},{"key":"2024102020245561000_37.3.690.198","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00047805"},{"key":"2024102020245561000_37.3.690.199","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200901-0153OC"},{"key":"2024102020245561000_37.3.690.200","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1164\/ajrccm\/137.1.215","article-title":"Isoniazid for the tuberculin reactor: take it or leave it","volume":"137","author":"Tsevat","year":"1988","journal-title":"Am Rev Respir Dis"},{"key":"2024102020245561000_37.3.690.201","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2009.07.008"},{"key":"2024102020245561000_37.3.690.202","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1986.03370120057023"},{"key":"2024102020245561000_37.3.690.203","doi-asserted-by":"publisher","DOI":"10.1086\/380966"},{"key":"2024102020245561000_37.3.690.204","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1164\/ajrccm.155.2.9032198","article-title":"Directly observed isoniazid preventive therapy for released jail inmates","volume":"155","author":"Nolan","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102020245561000_37.3.690.205","doi-asserted-by":"publisher","DOI":"10.1378\/chest.121.6.1771"},{"key":"2024102020245561000_37.3.690.206","doi-asserted-by":"crossref","first-page":"779","DOI":"10.7326\/0003-4819-129-10-199811150-00005","article-title":"Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis","volume":"129","author":"Rose","year":"1998","journal-title":"Ann Intern Med"},{"key":"2024102020245561000_37.3.690.207","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1164\/ajrccm\/137.1.2","article-title":"Decision analysis for isoniazid preventive therapy: take it or leave it?","volume":"137","author":"Snider","year":"1988","journal-title":"Am Rev Respir Dis"},{"key":"2024102020245561000_37.3.690.208","first-page":"927","article-title":"Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues","volume":"13","author":"A\u00eft-Khaled","year":"2009","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102020245561000_37.3.690.209","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66422-7"},{"key":"2024102020245561000_37.3.690.210","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2009.126771"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/09031936.00079310","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T06:25:35Z","timestamp":1740378335000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/09031936.00079310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,6]]},"references-count":210,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2011,2,28]]},"published-print":{"date-parts":[[2011,3]]}},"alternative-id":["10.1183\/09031936.00079310"],"URL":"https:\/\/doi.org\/10.1183\/09031936.00079310","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,6]]}}}